KR102699167B1 - Oat sprout postbiotic composition having skin whitening and wrinkle improvement activity and use thereof - Google Patents
Oat sprout postbiotic composition having skin whitening and wrinkle improvement activity and use thereof Download PDFInfo
- Publication number
- KR102699167B1 KR102699167B1 KR1020220024866A KR20220024866A KR102699167B1 KR 102699167 B1 KR102699167 B1 KR 102699167B1 KR 1020220024866 A KR1020220024866 A KR 1020220024866A KR 20220024866 A KR20220024866 A KR 20220024866A KR 102699167 B1 KR102699167 B1 KR 102699167B1
- Authority
- KR
- South Korea
- Prior art keywords
- whitening
- cosmetic composition
- wrinkle improvement
- lactobacillus
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 230000002087 whitening effect Effects 0.000 title claims abstract description 24
- 230000037303 wrinkles Effects 0.000 title claims abstract description 21
- 230000006872 improvement Effects 0.000 title claims abstract description 19
- 230000000694 effects Effects 0.000 title abstract description 35
- 239000002537 cosmetic Substances 0.000 claims abstract description 21
- 235000007319 Avena orientalis Nutrition 0.000 claims description 52
- 244000075850 Avena orientalis Species 0.000 claims description 38
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 19
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 18
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 18
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 10
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 9
- 244000199866 Lactobacillus casei Species 0.000 claims description 8
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 8
- 229940017800 lactobacillus casei Drugs 0.000 claims description 8
- 238000000855 fermentation Methods 0.000 claims description 5
- 230000004151 fermentation Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000000052 comparative effect Effects 0.000 description 43
- 230000005764 inhibitory process Effects 0.000 description 34
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
- 102000003425 Tyrosinase Human genes 0.000 description 17
- 108060008724 Tyrosinase Proteins 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 16
- 102000029816 Collagenase Human genes 0.000 description 15
- 108060005980 Collagenase Proteins 0.000 description 15
- 229960002424 collagenase Drugs 0.000 description 15
- 241000209761 Avena Species 0.000 description 14
- 238000002835 absorbance Methods 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 102000016387 Pancreatic elastase Human genes 0.000 description 12
- 108010067372 Pancreatic elastase Proteins 0.000 description 11
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 238000012258 culturing Methods 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 9
- 235000014655 lactic acid Nutrition 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 5
- 241000186660 Lactobacillus Species 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
- 235000011130 ammonium sulphate Nutrition 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000035784 germination Effects 0.000 description 5
- 229960001031 glucose Drugs 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229960000271 arbutin Drugs 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- IDUUXROOZBOOPH-QHHAFSJGSA-N 2-{[(2E)-3-(3,4-dihydroxyphenyl)-1-hydroxyprop-2-en-1-ylidene]amino}-5-hydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1NC(=O)\C=C\C1=CC=C(O)C(O)=C1 IDUUXROOZBOOPH-QHHAFSJGSA-N 0.000 description 3
- 229930190481 Avenanthramide Natural products 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- -1 conditioners Substances 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
- LWXNQQIVUUSCSL-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol trihydrochloride Chemical compound Cl.Cl.Cl.OCC(N)(CO)CO LWXNQQIVUUSCSL-UHFFFAOYSA-N 0.000 description 1
- GVUGADOWXGKRAE-SRVKXCTJSA-N 4-[[(2s)-1-[[(2s)-1-[[(2s)-1-(4-nitroanilino)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 GVUGADOWXGKRAE-SRVKXCTJSA-N 0.000 description 1
- 108010027805 Azocoll Proteins 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 101710205374 Extracellular elastase Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000021148 sequestering of metal ion Effects 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003890 substance P antagonist Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 피부 미백 및 주름개선 활성을 갖는 새싹귀리 포스트바이오틱스 조성물 및 이의 용도에 관한 것으로, 피부 미백 효능 및 주름개선 효능이 우수하므로 기능성 화장료 조성물로 유용하게 활용될 수 있다.The present invention relates to a sprouted oat postbiotics composition having skin whitening and wrinkle improvement activities and a use thereof. Since the composition has excellent skin whitening and wrinkle improvement effects, it can be usefully utilized as a functional cosmetic composition.
Description
본 발명은 피부 미백 및 주름개선 활성을 갖는 새싹귀리 포스트바이오틱스 조성물 및 이의 용도에 관한 것이다.The present invention relates to a sprouted oat postbiotics composition having skin whitening and wrinkle improvement activities and its use.
사람의 피부는 신체의 가장 외부에 위치하여 외모의 큰 비율을 차지하고 있으며, 지속적으로 외부로부터의 자극에 노출된다. 최근 소비자의 소득 및 지적 수준이 높아짐에 따라 피부 미용 건강에 대한 관심이 다양한 연령층에서 높은 수준으로 증가하고 있으며, 미백, 주름개선, 자외선 차단 등 보다 전문적이고 구체적인 기능이 부각된 화장품이 다양하게 개발되고 있다.The human skin is located on the outermost part of the body, accounts for a large proportion of the appearance, and is constantly exposed to external stimuli. Recently, as the income and intellectual level of consumers have increased, interest in skin beauty and health has increased to a high level across various age groups, and various cosmetics with more specialized and specific functions such as whitening, wrinkle improvement, and UV protection are being developed.
사람의 피부색은 검은 색소인 멜라닌(melanin)의 피부 내 농도 및 분포에 따라 결정되는데, 멜라닌은 피부 표피 층에 있는 멜라노사이트에서 합성된다. 멜라노사이트 내 소기관인 멜라노좀(melanosome)에서 아미노산의 일종인 티로신(tyrosine)에 티로시나제(tyrosinase)라는 효소가 작용하면 도파(DOPA), 도파퀴논(dopaquinone)으로 바뀐 후 비효소적인 산화반응을 거쳐 멜라닌이 생성된다. 멜라닌의 과잉 생산이 이루어지면 피부색이 짙어지고, 기미, 주근깨 등을 발생시키므로, 피부 내의 티로시나아제 활성을 저해함으로써 멜라닌의 생성 및 축적을 억제하면 피부 미백을 실현할 수 있다.Human skin color is determined by the concentration and distribution of the black pigment melanin in the skin, and melanin is synthesized in melanocytes in the epidermal layer of the skin. In the melanosome, an organelle within the melanocyte, tyrosine, an amino acid, is converted into DOPA and dopaquinone by an enzyme called tyrosinase, which then undergoes a non-enzymatic oxidation reaction to produce melanin. If melanin is overproduced, the skin color darkens and freckles and other signs occur, so by inhibiting the activity of tyrosinase in the skin, the production and accumulation of melanin can be suppressed, resulting in skin whitening.
피부 노화는 크게 내적 노화와 외적 노화에 의해 발생하며, 내적 노화는 나이가 들어감에 따라 신진대사를 조절하는 각종 호르몬 분비의 감소, 면역 세포의 기능 및 세포 활성 저하 등이 원인이며, 외적 노화는 자외선, 환경오염 등 외부적인 요인에 의해 자유 라디칼 및 활성 유해 산소 등이 증가함으로써 발생한다. 이러한 피부노화는 생체 내에서 콜라겐, 엘라스틴과 같은 세포외기질의 합성과 분해가 적절하게 조절되지 못하거나, 노화가 진행되면서 그 합성이 감소하며, 세포외 기질에 존재하는 콜라겐 섬유를 분해하는 효소인 콜라게나제(collagenase) 및 엘라스틴을 분해하는 효소인 엘라스타제(elastase)의 발현이 촉진됨에 따라 피부의 탄력이 저하되고 주름이 형성될 수 있다.Skin aging is largely caused by intrinsic aging and extrinsic aging. Intrinsic aging is caused by a decrease in the secretion of various hormones that control metabolism, a decrease in the function of immune cells, and a decrease in cell activity as we age. Extrinsic aging is caused by an increase in free radicals and reactive oxygen species due to external factors such as ultraviolet rays and environmental pollution. Such skin aging can occur when the synthesis and decomposition of extracellular matrices such as collagen and elastin in the body are not properly regulated, or when their synthesis decreases as aging progresses, and when the expression of collagenase, an enzyme that decomposes collagen fibers present in the extracellular matrix, and elastase, an enzyme that decomposes elastin, is promoted, which can cause a decrease in skin elasticity and the formation of wrinkles.
귀리(Avena sativa)는 다른 곡류에 비해 단백질, 필수아미노산, 수용성 섬유질이 풍부하며, 폴리페놀류 중 하나인 아베난쓰라마이드(avenanthramide) 성분은 특이적으로 귀리에만 존재하는 것으로 알려져 있다. 아베난쓰라마이드는 A, B, C, D 4가지 타입이 존재하며 최근 연구결과에서 아베난쓰라마이드 C의 미백 효능이 검증된 바 있다. 귀리가 발아하면서 자란 녹색 새싹인 새싹귀리는 귀리보다 폴리페놀의 함량이 증가한다고 알려져 있으며, 아베난쓰라마이드 또한 발아 전에 비해 발아 후에 농도가 월등히 높아진다고 알려져 있으나, 새싹귀리를 사용한 미백 및 주름완화 효능에 대한 연구결과는 미미한 실정이다.Oats ( Avena sativa ) are rich in protein, essential amino acids, and soluble fiber compared to other grains, and avenanthramide, a polyphenol component, is known to exist only in oats. There are four types of avenanthramides: A, B, C, and D, and recent research has verified the whitening effect of avenanthramide C. It is known that oat sprouts, which are green sprouts that grow when oats sprout, have a higher polyphenol content than oats, and the concentration of avenanthramide is also known to be significantly higher after germination than before germination, but research results on the whitening and wrinkle-relief effects using oat sprouts are minimal.
한편, 유산균은 자연계에 널리 존재하며 탄수화물을 혐기적으로 이용하여 유산을 생산할 수 있는 미생물로, 포스트바이오틱스(postbiotics)는 유산균이 발효 과정 등에서 만들어내는 부산물이나 유산균의 균체 성분이다. 최근 포스트바이오틱스는 식품, 영양제, 건강기능식품 및 의약품 등 다양한 상업적 용도로 개발되고 있으나, 화장료로써 새싹귀리의 발효를 위한 구체적인 균주 및 발효 조건 등에 대한 연구는 전무한 실정이다.Meanwhile, lactic acid bacteria are widely present in nature and are microorganisms that can produce lactic acid by anaerobically utilizing carbohydrates, while postbiotics are byproducts or lactic acid bacteria cell components produced by lactic acid bacteria during the fermentation process. Recently, postbiotics have been developed for various commercial purposes such as food, nutritional supplements, health functional foods, and pharmaceuticals, but there has been no research on specific strains and fermentation conditions for fermentation of sprouted oats as cosmetics.
이에 따라, 본 발명자들은 새싹귀리 추출물에 유산균을 접종하여 배양한 뒤, 새싹귀리 발효액을 사용하여 우수한 피부 미백 및 주름개선 활성을 나타내는 포스트바이오틱스 조성물을 제조하기 위한 연구를 수행하여 본 발명을 완성하였다.Accordingly, the inventors of the present invention conducted research to manufacture a postbiotics composition exhibiting excellent skin whitening and wrinkle improvement activities by inoculating lactic acid bacteria into sprout extract and culturing it, and then using sprout fermented solution of oat sprout, thereby completing the present invention.
본 발명의 목적은 새싹귀리 발효물을 포함하는 미백 및 주름개선용 화장료 조성물을 제공하는 것이다.The purpose of the present invention is to provide a cosmetic composition for whitening and improving wrinkles containing fermented sprouted oats.
본 발명의 일 양상은 새싹귀리 발효물을 포함하는 미백 및 주름개선용 화장료 조성물을 제공한다. One aspect of the present invention provides a whitening and wrinkle-improving cosmetic composition containing fermented sprouted oats.
본 발명에서 사용되는 새싹귀리는 귀리(Avena sativa)의 어린잎으로, 발아 후 7 내지 10일에 수확한 것일 수 있다.The sprouted oats used in the present invention are young leaves of oats ( Avena sativa ), and may be harvested 7 to 10 days after germination.
본 발명의 일 구체예에 따르면, 상기 새싹귀리 발효물은 새싹귀리 추출물을 발효한 것일 수 있다. According to one specific example of the present invention, the fermented oat sprout may be a product obtained by fermenting an oat sprout extract.
본 발명에 따른 조성물에 포함되는 추출물은 새싹귀리 분말을 적절한 양의 용매에 첨가하여, 100 내지 140℃에서 10 내지 20분간 추출하여 수득될 수 있다. The extract included in the composition according to the present invention can be obtained by adding sprouted oat powder to an appropriate amount of solvent and extracting at 100 to 140°C for 10 to 20 minutes.
상기 새싹귀리 분말은 발아 후 7 내지 10일에 수확한 새싹귀리를 건조 후 분쇄하여 사용하거나, 시판되는 새싹귀리 분말을 구매하여 사용할 수 있다.The above sprouted oat powder can be used by drying and grinding sprouted oats harvested 7 to 10 days after germination, or by purchasing commercially available sprouted oat powder.
본 발명의 일 구체예에 따르면, 상기 새싹귀리 추출물은 물, 탄소수 1 내지 4의 알코올 및 이들의 혼합물로 이루어진 군에서 선택되는 용매로 추출될 수 있다.According to one specific example of the present invention, the sprouted oat extract can be extracted with a solvent selected from the group consisting of water, alcohols having 1 to 4 carbon atoms, and mixtures thereof.
상기 용매는 바람직하게는 물일 수 있고, 더욱 바람직하게는 증류수일 수 있다.The solvent may preferably be water, and more preferably distilled water.
본 발명의 일 구체예에 따르면, 상기 새싹귀리 발효물은 35 내지 40℃에서 40 내지 80시간 동안 배양된 것일 수 있다.According to one specific example of the present invention, the fermented oat sprouts may be cultured at 35 to 40°C for 40 to 80 hours.
본 발명의 일 구체예에 따르면, 상기 발효는 락토바실러스 플란타룸(Lactobacillus plantarum), 락토바실러스 람노서스(Lactobacillus rhamnosus), 락토바실러스 카세이(Lactobacillus casei) 및 락토바실러스 가세리(Lactobacillus gasseri)으로 이루어진 군으로부터 선택되는 어느 하나의 균주로 이루어질 수 있으나 이에 한정되지 않는다.According to one specific example of the present invention, the fermentation may be performed using any one strain selected from the group consisting of Lactobacillus plantarum, Lactobacillus rhamnosus , Lactobacillus casei , and Lactobacillus gasseri, but is not limited thereto.
본 발명의 일 구체예에 따르면, 상기 새싹귀리 발효물은 화장료 조성물 100 중량부에 대하여 0.01 내지 30.0 중량부로 포함될 수 있다.According to one specific example of the present invention, the fermented oat sprout may be included in an amount of 0.01 to 30.0 parts by weight per 100 parts by weight of the cosmetic composition.
본 발명의 화장료 조성물은 당업계의 통상적인 제형으로 제조될 수 있으며, 예를 들어 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이의 제형일 수 있으나 이에 한정되지 않는다.The cosmetic composition of the present invention can be prepared in a conventional formulation in the art, and may be, for example, but is not limited to, in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, and spray.
또한, 본 발명의 화장료 조성물은, 예를 들어, 하이드로겔, 접착용 패치, 비-접착용 패치, 마이크로전자 패치 또는 얼굴 마스크와 같은 다른 종류의 고체 용구에 당해 분야의 기술자에게 알려진 사용 기술을 사용하여 포함될 수 있거나, 메이크업 파운데이션, 예를 들어, 유체 파운데이션 및 콤팩트 파운데이션, 메이크업 제거용 로션, 메이크업 제거용 우유, 컨실러, 아이섀도, 립스틱, 립 프로텍터, 립 글로스 및 파우더와 같은 기타 메이크업 제품에 포함될 수 있다.Furthermore, the cosmetic composition of the present invention may be incorporated into other types of solid devices, such as, for example, hydrogels, adhesive patches, non-adhesive patches, microelectronic patches or facial masks, using techniques known to those skilled in the art, or may be incorporated into other makeup products, such as makeup foundations, for example, fluid foundations and compact foundations, makeup remover lotions, makeup remover milks, concealers, eye shadows, lipsticks, lip protectors, lip glosses and powders.
본 발명의 화장료 조성물은 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속 이온 봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품 분야에서 통상적으로 사용되는 보조제를 더 포함할 수 있다.The cosmetic composition of the present invention may further comprise adjuvants commonly used in the cosmetic field, such as fatty substances, organic solvents, solubilizers, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion sequestering and chelating agents, preservatives, vitamins, blocking agents, humectants, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other ingredients commonly used in cosmetics.
본 발명의 화장료 조성물은 그 제형의 제제화에 필요하고 적절한 각종 기제 및/또는 첨가물을 포함할 수 있으며, 그 효과를 떨어트리지 않는 범위 내에서 비이온 계면활성제, 실리콘 폴리머, 체질안료, 향료, 방부제, 살균제, 산화 안정화제, 유기 용매, 이온성 또는 비이온성 증점제, 유연화제, 산화방지제, 자유 라디칼 파괴제, 불투명화제, 안정화제, 에몰리언트(emollient), 실리콘, α-히드록시산, 소포제, 보습제, 비타민, 곤충 기피제, 향료, 보존제, 계면활성제, 소염제, 물질 P 길항제, 충전제, 중합체, 추진제, 염기성화 또는 산성화제, 또는 착색제 등 공지의 화합물을 더 포함하여 제조될 수 있다.The cosmetic composition of the present invention may contain various bases and/or additives necessary and appropriate for the formulation of the dosage form, and may be manufactured by further including known compounds such as nonionic surfactants, silicone polymers, conditioners, fragrances, preservatives, bactericides, oxidation stabilizers, organic solvents, ionic or nonionic thickeners, softeners, antioxidants, free radical scavengers, opacifiers, stabilizers, emollients, silicones, α-hydroxy acids, antifoaming agents, moisturizers, vitamins, insect repellents, fragrances, preservatives, surfactants, anti-inflammatory agents, substance P antagonists, fillers, polymers, propellants, alkalizing or acidifying agents, or colorants, within a range that does not reduce the effectiveness.
본 발명의 유산균을 이용해 발효되어 피부 미백 및 주름개선 활성을 갖는 새싹귀리 포스트바이오틱스 조성물은 피부 미백 효능 및 주름개선 효능이 우수하므로, 기능성 화장료 조성물로 유용하게 활용될 수 있다.The sprouted oat postbiotics composition, which is fermented using the lactic acid bacteria of the present invention and has skin whitening and wrinkle improvement activities, has excellent skin whitening and wrinkle improvement effects, and thus can be usefully utilized as a functional cosmetic composition.
도 1은 락토바실러스 플란타룸(Lactobacillus plantarum) KCTC3104 및 락토바실러스 플란타룸 KCTC3108를 배양하여 발효한 포스트바이오틱스 조성물의 티로시나아제 활성저해율을 나타낸 그래프이다.
도 2는 락토바실러스 람노서스(Lactobacillus rhamnosus) KCTC3237 및 락토바실러스 람노서스 KCTC5033를 배양하여 발효한 포스트바이오틱스 조성물의 티로시나아제 활성저해율을 나타낸 그래프이다.
도 3은 락토바실러스 카세이(Lactobacillus casei) KCTC3109을 배양하여 발효한 포스트바이오틱스 조성물의 티로시나아제 활성저해율을 나타낸 그래프이다.
도 4는 락토바실러스 가세리(Lactobacillus gasseri) KCTC3143을 배양하여 발효한 포스트바이오틱스 조성물의 티로시나아제 활성저해율을 나타낸 그래프이다.
도 5은 락토바실러스 플란타룸(Lactobacillus plantarum) KCTC3104, 락토바실러스 플란타룸 KCTC3108 및 락토바실러스 람노서스(Lactobacillus rhamnosus) KCTC3237를 배양하여 발효한 포스트바이오틱스 조성물의 엘타스타제 활성저해율을 나타낸 그래프이다.
도 6는 락토바실러스 람노서스 KCTC3237, 락토바실러스 람노서스 KCTC5033 및 락토바실러스 카세이(Lactobacillus casei) KCTC3109을 배양하여 발효한 포스트바이오틱스 조성물의 콜라게나제 활성저해율을 나타낸 그래프이다.
도 7은 락토바실러스 가세리(Lactobacillus gasseri) KCTC3143을 배양하여 발효한 포스트바이오틱스 조성물의 콜라게나제 활성저해율을 나타낸 그래프이다.Figure 1: Lactobacillus plantarum This is a graph showing the tyrosinase activity inhibition rate of a postbiotic composition fermented by culturing KCTC3104 and Lactobacillus plantarum KCTC3108.
Figure 2 is a graph showing the tyrosinase activity inhibition rate of a postbiotic composition fermented by culturing Lactobacillus rhamnosus KCTC3237 and Lactobacillus rhamnosus KCTC5033.
Figure 3 is a graph showing the tyrosinase activity inhibition rate of a postbiotic composition fermented by culturing Lactobacillus casei KCTC3109.
Figure 4 is a graph showing the tyrosinase activity inhibition rate of a postbiotic composition fermented by culturing Lactobacillus gasseri KCTC3143.
Figure 5 is a graph showing the inhibition rate of eltastase activity of a postbiotics composition fermented by culturing Lactobacillus plantarum KCTC3104, Lactobacillus plantarum KCTC3108, and Lactobacillus rhamnosus KCTC3237.
Figure 6 is a graph showing the collagenase activity inhibition rate of a postbiotics composition fermented by culturing Lactobacillus rhamnosus KCTC3237, Lactobacillus rhamnosus KCTC5033, and Lactobacillus casei KCTC3109.
Figure 7 is a graph showing the collagenase activity inhibition rate of a postbiotics composition fermented by culturing Lactobacillus gasseri KCTC3143.
이하 본 발명을 하나 이상의 실시예를 통하여 보다 상세하게 설명한다. 그러나, 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through one or more examples. However, these examples are intended to exemplify the present invention and the scope of the present invention is not limited to these examples.
실시예 1 및 2. 락토바실러스 플란타룸(Examples 1 and 2. Lactobacillus plantarum ( Lactobacillus plantarumLactobacillus plantarum )으로 발효한 새싹귀리 포스트바이오틱스 조성물 제조) Manufacturing of a postbiotic composition of sprouted oats fermented with
농도별 새싹귀리(Avena sativa) 추출물을 제조하고, 락토바실러스 플란타룸(Lactobacillus plantarum) KCTC3104 및 락토바실러스 플란타룸 KCTC3108을 각각 배양하여 포스트바이오틱스 조성물을 제조하였다.Preparation of sprouted oat ( Avena sativa ) extract by concentration and Lactobacillus plantarum Postbiotic compositions were prepared by culturing KCTC3104 and Lactobacillus plantarum KCTC3108, respectively.
구체적으로, 발아 후 10일이 경과한 새싹귀리 분말을 2.5% w/w(a), 5% w/w(b), 10% w/w(c) 농도로 증류수에 넣은 후, 고압멸균기로 121℃에서 15분간 추출 및 살균하여 새싹귀리 열수추출물을 수득하였다.Specifically, sprouted oat powder that had been germinated for 10 days was added to distilled water at concentrations of 2.5% w/w (a), 5% w/w (b), and 10% w/w (c), and then extracted and sterilized in an autoclave at 121°C for 15 minutes to obtain a sprouted oat hot water extract.
증류수에 세척한 1.0×109 CFU/㎖의 락토바실러스 플란타룸 KCTC3104 및 락토바실러스 플란타룸 KCTC3108을 주입하고 진탕배양기로 37℃, 75rpm에서 48시간 동안 배양하였다. 균주의 영양분으로 포도당 일수화물(glucose monohydrate, 7.5% w/w) 및 황산암모늄(ammonium sulfate, 3% w/w)를 첨가하였다. 배양 후 상층액을 Whatman Grade No.2 여과지 및 pore size 0.2㎛의 시린지필터(syringe filter)로 여과하여 실시예 1 및 2를 제조하였다. 음성대조군으로는 포도당 일수화물 및 황산암모늄을 넣은 증류수를 사용하였다.1.0× 109 CFU/㎖ of Lactobacillus plantarum KCTC3104 and Lactobacillus plantarum KCTC3108, washed in distilled water, were injected and cultured in a shaking incubator at 37℃ and 75 rpm for 48 hours. Glucose monohydrate (7.5% w/w) and ammonium sulfate (3% w/w) were added as nutrients for the strains. After culture, the supernatant was filtered through Whatman Grade No. 2 filter paper and a syringe filter with a pore size of 0.2㎛, to prepare Examples 1 and 2. Distilled water containing glucose monohydrate and ammonium sulfate was used as a negative control.
실시예 3 및 4. 락토바실러스 람노서스(Examples 3 and 4. Lactobacillus rhamnosus ( Lactobacillus rhamnosusLactobacillus rhamnosus )로 발효한 새싹귀리 포스트바이오틱스 조성물 제조) Manufacturing of a postbiotic composition of sprouted oats fermented with
락토바실러스 람노서스(Lactobacillus rhamnosus) KCTC3237 및 락토바실러스 람노서스 KCTC5033 균주를 사용하여 72시간 배양한 것을 제외하면 실시예 1과 동일한 방법으로 제조하였다. 음성대조군으로는 포도당 일수화물 및 황산암모늄을 넣은 증류수를 사용하였다.It was prepared in the same manner as Example 1, except that Lactobacillus rhamnosus KCTC3237 and Lactobacillus rhamnosus KCTC5033 strains were used and cultured for 72 hours. Distilled water containing glucose monohydrate and ammonium sulfate was used as a negative control.
실시예 5. 락토바실러스 카세이(Example 5. Lactobacillus casei ( Lactobacillus caseiLactobacillus casei )로 발효한 새싹귀리 포스트바이오틱스 조성물 제조) Manufacturing of a postbiotic composition of sprouted oats fermented with
락토바실러스 카세이(Lactobacillus casei) KCTC3109를 사용한 것을 제외하면 실시예 1과 동일한 방법으로 제조하였다. 음성대조군으로는 포도당 일수화물 및 황산암모늄을 넣은 증류수를 사용하였다.It was manufactured in the same manner as Example 1, except that Lactobacillus casei KCTC3109 was used. Distilled water containing glucose monohydrate and ammonium sulfate was used as a negative control group.
실시예 6 및 7. 락토바실러스 가세리(Examples 6 and 7. Lactobacillus gasseri ( Lactobacillus gasseriLactobacillus gasseri )로 발효한 새싹귀리 포스트바이오틱스 조성물 제조) Manufacturing of a postbiotic composition of sprouted oats fermented with
락토바실러스 가세리(Lactobacillus gasseri) KCTC3143 균주를 사용하여 48시간(실시예 6) 또는 72시간(실시예 7) 배양한 것을 제외하면 실시예 1과 동일한 방법으로 제조하였다. 음성대조군으로는 포도당 일수화물 및 황산암모늄을 넣은 증류수를 사용하였다.It was prepared in the same manner as Example 1, except that Lactobacillus gasseri KCTC3143 strain was used and cultured for 48 hours (Example 6) or 72 hours (Example 7). Distilled water containing glucose monohydrate and ammonium sulfate was used as a negative control.
(48h)Lactobacillus gasseriKCTC3143
(48h)
(72h)Lactobacillus gasseriKCTC3143
(72h)
비교예 1 내지 6. 비발효 새싹귀리 추출물 제조Comparative Examples 1 to 6. Preparation of non-fermented sprouted oat extract
발아 후 10일이 경과한 새싹귀리 분말을 2.5% w/w(a), 5% w/w(b), 10% w/w(c) 농도로 증류수에 넣은 후, 고압멸균기로 121℃에서 15분간 추출 및 살균하여 새싹귀리 열수추출물을 수득하였다. 증류수에 세척한 1.0×109 CFU/㎖의 락토바실러스 플란타룸 KCTC3104, 락토바실러스 플란타룸 KCTC3108, 락토바실러스 람노서스 KCTC3237, 락토바실러스 람노서스 KCTC5033, 락토바실러스 카세이 KCTC3109 및 락토바실러스 가세리 KCTC3143를 실험 직전 새싹귀리 추출물에 혼합하여 사용하였다(비교예 1 내지 6).After 10 days of germination, sprouted oat powder was added to distilled water at concentrations of 2.5% w/w (a), 5% w/w (b), and 10% w/w (c), and then extracted and sterilized in an autoclave at 121°C for 15 minutes to obtain a sprouted oat hot water extract. 1.0× 109 CFU/㎖ of Lactobacillus plantarum KCTC3104, Lactobacillus plantarum KCTC3108, washed in distilled water, Lactobacillus rhamnosus KCTC3237, Lactobacillus rhamnosus KCTC5033, Lactobacillus casei KCTC3109, and Lactobacillus gasseri KCTC3143 were mixed with sprouted oat extract and used immediately before the experiment (Comparative Examples 1 to 6).
실험예 1. 새싹귀리 포스트바이오틱스 조성물의 우수한 티로시나아제 활성 저해능 측정Experimental Example 1. Measurement of the excellent tyrosinase activity inhibition ability of the sprout oat postbiotics composition
실시예 1 내지 7 및 비교예 1 내지 6의 피부 미백 효능을 확인하기 위하여, 멜라닌의 생합성에 관여하는 주요 효소인 티로시나아제 활성 저해 시험(Tyrosinase Inhibitory Assay)을 수행하였다.In order to confirm the skin whitening efficacy of Examples 1 to 7 and Comparative Examples 1 to 6, a Tyrosinase Inhibitory Assay, a major enzyme involved in the biosynthesis of melanin, was performed.
구체적으로, 각 e-tube에 pH 6.8의 0.1M 인산염완충액 660㎕를 주입하고, 각 e-tube에 실시예 1 내지 7 및 비교예 1 내지 6를 60㎕씩 처리한 뒤 각 e-tube에 티로시나아제(750U/㎖)를 90㎕씩 처리하였다. 이후에 각 e-tube에 1.5mM L-tyrosine을 90㎕씩 처리하고 37℃에서 12분 동안 반응시켰다. 양성대조군으로는 실시예 1 내지 7 및 비교예 1 내지 6 대신 미백 고시원료인 누룩산(Kojic acid) 또는 알부틴(arbutin) 60㎕을 동일한 방법으로 처리하여 준비하였으며, 음성대조군으로는 실시예 1 내지 7 및 비교예 1 내지 6 대신 pH 6.8의 0.1M 인산염완충액 60㎕를 추가로 주입하여 동일한 방법으로 처리하여 준비하였다.Specifically, 660 ㎕ of 0.1 M phosphate buffer at pH 6.8 was injected into each e-tube, 60 ㎕ of Examples 1 to 7 and Comparative Examples 1 to 6 were treated into each e-tube, and 90 ㎕ of tyrosinase (750 U/㎖) was treated into each e-tube. Thereafter, 90 ㎕ of 1.5 mM L-tyrosine was treated into each e-tube and reacted at 37°C for 12 minutes. As a positive control group, 60 ㎕ of kojic acid or arbutin, a whitening raw material, was prepared by treating it in the same manner instead of Examples 1 to 7 and Comparative Examples 1 to 6, and as a negative control group, 60 ㎕ of 0.1 M phosphate buffer at pH 6.8 was additionally injected instead of Examples 1 to 7 and Comparative Examples 1 to 6 and treated in the same manner.
반응이 완료된 후, 96well plate에 150ul씩 분주하여 490㎚에서 멜라닌 생합성 기전에서 티로시나아제에 의해 생성되는 중간체인 도파크롬(Dopachrome)의 흡광도를 측정하여 하기의 식에 따라 티로시나아제 활성저해율을 측정하였다.After the reaction was completed, 150 μl was dispensed into each 96-well plate, and the absorbance of dopachrome, an intermediate produced by tyrosinase in the melanin biosynthesis pathway, was measured at 490 nm to determine the tyrosinase activity inhibition rate according to the following formula.
티로시나아제 활성저해율(%) = Tyrosinase activity inhibition rate (%) =
a: 공시료액의 반응 후의 흡광도a: Absorbance after reaction of the blank sample solution
b: 샘플의 반응 후의 흡광도b: Absorbance after reaction of the sample
a', b': 티로시나아제 대신 완충액으로 대체하여 측정한 흡광도a', b': Absorbance measured by replacing tyrosinase with buffer
분석 결과, 실시예 1 내지 5는 모든 농도에서 동일한 농도의 비교예보다 높은 티로시나아제 활성저해율을 보였으며, 모든 농도에서 양성대조군인 누룩산보다 티로시나아제 활성저해율이 높은 것으로 나타났다. 또한, 실시예 6 내지 7은 모든 농도에서 동일한 농도의 비교예 6보다 높은 티로시나아제 활성저해율을 보였으며, 모든 농도에서 양성대조군인 알부틴보다 티로시나아제 활성저해율이 높은 것으로 나타났다.As a result of the analysis, Examples 1 to 5 showed higher tyrosinase activity inhibition rates than the comparative examples at the same concentration at all concentrations, and showed higher tyrosinase activity inhibition rates than the positive control group, nuruk-san at all concentrations. In addition, Examples 6 to 7 showed higher tyrosinase activity inhibition rates than the comparative example 6 at the same concentration at all concentrations, and showed higher tyrosinase activity inhibition rates than the positive control group, arbutin at all concentrations.
특히, 실시예 1(c) 는 비교예 1(c) 대비 1.75배, 실시예 2(c)는 비교예 2(c) 대비 1.84배 증가하였으며(도 1), 실시예 3(c)는 3.02배, 실시예 4(c)는 비교예 4(c) 대비 2.86배 높은 저해율을 보였고(도 2), 실시예 5(b)는 비교예 5(b) 보다 1.64배 높은 저해율을 나타내었다(도 3). 또한, 실시예 6(c)는 저해율이 비교예 6(c) 대비 2.86배, 알부틴 대비 1.99배 높게 나타났으며, 실시예 7(c)는 비교예 6(c) 대비 2.58배, 알부틴 대비 1.92배 저해율이 증가한 것(도 4)을 확인할 수 있었다.In particular, Example 1(c) showed a 1.75-fold increase compared to Comparative Example 1(c), Example 2(c) showed a 1.84-fold increase compared to Comparative Example 2(c) (Fig. 1), Example 3(c) showed a 3.02-fold increase, Example 4(c) showed a 2.86-fold increase in inhibition rate compared to Comparative Example 4(c) (Fig. 2), and Example 5(b) showed a 1.64-fold increase in inhibition rate compared to Comparative Example 5(b) (Fig. 3). In addition, Example 6(c) showed a 2.86-fold increase in inhibition rate compared to Comparative Example 6(c) and a 1.99-fold increase in inhibition rate compared to arbutin, and Example 7(c) showed a 2.58-fold increase in inhibition rate compared to Comparative Example 6(c) and a 1.92-fold increase in inhibition rate compared to arbutin (Fig. 4).
이와 같은 결과를 통하여, 새싹귀리 포스트바이오틱스 조성물의 피부 미백효능이 우수하며, 다양한 유산균으로 발효한 새싹귀리 포스트바이오틱스 조성물 중 락토바실러스 람노서스 KCTC5033을 주입하여 72시간 발효한 새싹귀리 포스트바이오틱스 조성물의 피부 미백 효능이 특히 우수한 것으로 확인되었다.Through these results, it was confirmed that the skin whitening effect of the oat sprout postbiotics composition was excellent, and among the oat sprout postbiotics compositions fermented with various lactic acid bacteria, the skin whitening effect of the oat sprout postbiotics composition fermented for 72 hours by injecting Lactobacillus rhamnosus KCTC5033 was particularly excellent.
실험예 2. 새싹귀리 포스트바이오틱스 조성물의 우수한 엘라스타제 활성 저해능 측정Experimental Example 2. Measurement of the excellent elastase activity inhibition ability of the sprouted oat postbiotics composition
실시예 1 내지 3 및 비교예 1 내지 3의 주름개선 효능을 확인하기 위하여, 자외선에 의한 피부 탄성도 감소 및 주름 생성의 주요원인인 엘라스타제 활성 저해 시험(Elastase Inhibitory Assay)을 수행하였다.In order to confirm the wrinkle improvement efficacy of Examples 1 to 3 and Comparative Examples 1 to 3, an elastase inhibition assay, which is a major cause of decreased skin elasticity and wrinkle formation due to ultraviolet rays, was performed.
구체적으로, 96 well plate에 pH 8의 0.1232M Tris-HCl(2-Amino-2-(hydroxymethyl)propane-1,3-diol)에 용해한 1.015mM N-succinyl Ala-Ala-Ala-p-nitroanilide를 200㎕씩 처리하였다. 각 well에 실시예 1 내지 3 및 비교예 1 내지 3를 10㎕씩 처리한 뒤 25℃에서 10분 동안 방치하였다. 이후 각 well에 엘라스타제(3U/㎖)를 10㎕씩 처리하여 25℃에서 10분 동안 반응시켰다. 양성대조군으로는 실시예 1 내지 3 및 비교예 1 내지 3 대신 항산화능이 우수한 것으로 알려진 EGCG(Epigallocatechin-3-gallate) 10㎕를 동일한 방법으로 처리하여 준비하였다.Specifically, 200 ㎕ of 1.015 mM N-succinyl Ala-Ala-Ala-p-nitroanilide dissolved in 0.1232 M Tris-HCl (2-Amino-2-(hydroxymethyl)propane-1,3-diol) at pH 8 was treated in a 96-well plate. 10 ㎕ of Examples 1 to 3 and Comparative Examples 1 to 3 were treated to each well, and then left to stand at 25°C for 10 minutes. Thereafter, 10 ㎕ of elastase (3 U/㎖) was treated to each well, and the reaction was performed at 25°C for 10 minutes. As a positive control group, 10 ㎕ of EGCG (Epigallocatechin-3-gallate), known to have excellent antioxidant activity, was prepared by treating it in the same manner instead of Examples 1 to 3 and Comparative Examples 1 to 3.
반응이 완료된 후, 410㎚에서 파라-니트로아닐린(4-nitroaniline)의 흡광도(B)를 측정하여 하기의 식에 따라 엘라스타제 활성저해율을 측정하였다. 완충액은 실시예 1 내지 3 및 비교예 1 내지 3과 동일하게 pH 8의 0.1232M Tris-HCl을 사용하였다.After the reaction was completed, the absorbance (B) of para-nitroaniline (4-nitroaniline) was measured at 410 nm, and the elastase activity inhibition rate was measured according to the following formula. The buffer solution used was 0.1232 M Tris-HCl at pH 8, the same as in Examples 1 to 3 and Comparative Examples 1 to 3.
엘라스타제 활성저해율(%) = Elastase activity inhibition rate (%) =
A: 시료 대신 완충액을 넣고 엘라스타제를 첨가하여 반응한 후의 흡광도A: Absorbance after reaction by adding elastase instead of a sample and adding a buffer solution
B: 엘라스타제를 첨가하여 반응한 후의 시료의 흡광도B: Absorbance of the sample after reaction with elastase added
C: 엘라스타제 대신 완충액을 첨가하여 반응한 후의 시료의 흡광도C: Absorbance of the sample after reaction by adding buffer instead of elastase
D: 시료와 엘라스타제 대신 각각 완충액을 첨가해 반응한 후의 흡광도D: Absorbance after reaction with buffer added instead of sample and elastase
분석 결과, 실시예 1 내지 3은 모든 농도에서 동일한 농도의 비교예보다 엘라스타제 활성저해율이 높은 것으로 나타났으며, 실시예 2(c) 및 실시예 3(a) 내지 3(c)는 양성대조군인 EGCG보다 높은 저해율을 나타내는 것을 확인할 수 있었다(도 5). 특히, 실시예 3(c)는 실시예 1 내지 3 중 엘라스타제 활성저해율이 가장 높게 나타났으며, 비교예 3(c) 대비 2배 증가하였다.As a result of the analysis, Examples 1 to 3 showed higher elastase activity inhibition rates than the comparative examples at the same concentration at all concentrations, and it was confirmed that Examples 2(c) and Examples 3(a) to 3(c) showed higher inhibition rates than the positive control group, EGCG (Fig. 5). In particular, Example 3(c) showed the highest elastase activity inhibition rate among Examples 1 to 3, and increased by 2 times compared to Comparative Example 3(c).
이와 같은 결과를 통하여, 새싹귀리 포스트바이오틱스 조성물의 주름개선 효능이 우수하며, 다양한 유산균으로 발효한 새싹귀리 포스트바이오틱스 조성물 중 락토바실러스 람노서스 KCTC3237을 주입하여 72시간 발효한 새싹귀리 포스트바이오틱스 조성물의 주름개선 효능이 특히 우수한 것으로 확인되었다.Through these results, it was confirmed that the wrinkle improvement efficacy of the oat sprout postbiotics composition was excellent, and among the oat sprout postbiotics compositions fermented with various lactic acid bacteria, the wrinkle improvement efficacy of the oat sprout postbiotics composition fermented for 72 hours by injecting Lactobacillus rhamnosus KCTC3237 was particularly excellent.
실험예 3. 새싹귀리 포스트바이오틱스 조성물의 우수한 콜라게나제 활성 저해능 측정Experimental Example 3. Measurement of excellent collagenase activity inhibition ability of sprouted oat postbiotics composition
실시예 3 내지 7 및 비교예 3 내지 6의 주름개선 효능을 확인하기 위하여, 세포외 기질에 존재하는 콜라겐 섬유를 분해하여 주름 생성의 주요 원인이 되는 콜라게나제 활성 저해 시험(Collagenase Inhibitory Assay)을 수행하였다.In order to confirm the wrinkle improvement efficacy of Examples 3 to 7 and Comparative Examples 3 to 6, a collagenase inhibition assay was performed to decompose collagen fibers present in the extracellular matrix and to determine the main cause of wrinkle formation.
구체적으로, 각 e-tube에 pH 7의 0.1M Tris-HCl 800㎕를 주입하고, 1㎎의 아조콜(azocoll, azo-dye impregnated collagen)을 첨가하여 녹였다. 각 e-tube에 실시예 3 내지 7 및 비교예 3 내지 6를 100㎕를 처리한 뒤, 100㎕의 콜라게나제(0.2㎎/㎖)를 처리하고 37℃에서 1시간 동안 교반하여 반응시켰다. 양성대조군으로는 실시예 3 내지 7 및 비교예 3 내지 6 대신 EGCG 100㎕를 동일한 방법으로 처리하여 준비하였다.Specifically, 800 ㎕ of 0.1 M Tris-HCl at pH 7 was injected into each e-tube, and 1 ㎎ of azocoll (azo-dye impregnated collagen) was added and dissolved. 100 ㎕ of Examples 3 to 7 and Comparative Examples 3 to 6 were treated into each e-tube, and then 100 ㎕ of collagenase (0.2 ㎎/㎖) was treated and stirred at 37℃ for 1 hour to react. As a positive control group, 100 ㎕ of EGCG was prepared by treating it in the same manner instead of Examples 3 to 7 and Comparative Examples 3 to 6.
반응이 완료된 후, 각 e-tube를 10,000rpm에서 10분 동안 원심분리하고, 96 well plate에 상등액을 200㎕씩 분주하여 550nm에서 흡광도를 측정하였다. 상등액에는 분해된 콜라겐이 함유되어 있으며, 하기의 식에 따라 콜라게나제 활성저해율을 측정하였다. 완충액은 실시예 1 내지 3 및 비교예 1 내지 3과 동일하게 pH 7의 0.1M Tris-HCl을 사용하였다.After the reaction was completed, each e-tube was centrifuged at 10,000 rpm for 10 minutes, and 200 ㎕ of the supernatant was dispensed into a 96-well plate, and the absorbance was measured at 550 nm. The supernatant contained decomposed collagen, and the collagenase activity inhibition rate was measured according to the following formula. The buffer used was 0.1 M Tris-HCl at pH 7, the same as in Examples 1 to 3 and Comparative Examples 1 to 3.
콜라게나제 활성저해율(%) = Collagenase activity inhibition rate (%) =
A: 시료 대신 완충액을 넣고 콜라게나제를 첨가하여 반응한 후의 흡광도A: Absorbance after reaction by adding collagenase and replacing the sample with buffer
B: 콜라게나제를 첨가하여 반응한 후의 시료의 흡광도B: Absorbance of the sample after reaction with collagenase added
C: 콜라게나제 대신 완충액을 첨가하여 반응한 후의 시료의 흡광도C: Absorbance of the sample after reaction with buffer added instead of collagenase
D: 시료와 콜라게나제 대신 각각 완충액을 첨가해 반응한 후의 흡광도D: Absorbance after reaction with buffer added instead of sample and collagenase
분석 결과, 실시예 3 내지 7은 모든 농도에서 동일한 농도의 비교예보다 높은 콜라게나제 활성저해율을 보였으며, 모든 농도에서 양성대조군인 EGCG보다 콜라게나제 활성저해율이 높은 것으로 나타났다(도 6 및 7). 특히, 실시예 6(c)는 콜라게나제 활성저해율이 약 69%로 실시예 3 내지 7 중 가장 높게 나타났다.As a result of the analysis, Examples 3 to 7 showed higher collagenase activity inhibition rates than the comparative examples at the same concentration at all concentrations, and higher collagenase activity inhibition rates than the positive control group, EGCG, at all concentrations (Figs. 6 and 7). In particular, Example 6(c) showed the highest collagenase activity inhibition rate of about 69% among Examples 3 to 7.
이와 같은 결과를 통하여, 새싹귀리 포스트바이오틱스 조성물의 피부 주름개선 효능이 우수하며, 다양한 유산균으로 발효한 새싹귀리 포스트바이오틱스 조성물 중 락토바실러스 가세리 KCTC3143을 주입하여 48시간 발효한 새싹귀리 포스트바이오틱스 조성물의 주름개선 효능이 특히 우수한 것으로 확인되었다.Through these results, it was confirmed that the oat sprout postbiotics composition has excellent skin wrinkle improvement efficacy, and among the oat sprout postbiotics compositions fermented with various lactic acid bacteria, the oat sprout postbiotics composition fermented for 48 hours by injecting Lactobacillus gasseri KCTC3143 has particularly excellent wrinkle improvement efficacy.
이제까지 본 발명에 대하여 그 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.The present invention has been described with reference to embodiments thereof. Those skilled in the art will appreciate that the present invention may be implemented in modified forms without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered from an illustrative rather than a restrictive perspective. The scope of the present invention is set forth in the claims, not in the foregoing description, and all differences within the scope equivalent thereto should be construed as being included in the present invention.
Claims (7)
상기 발효는 락토바실러스 플란타룸(Lactobacillus plantarum), 락토바실러스 람노서스(Lactobacillus rhamnosus), 락토바실러스 카세이(Lactobacillus casei) 및 락토바실러스 가세리(Lactobacillus gasseri)로 이루어진 군으로부터 선택되는 어느 하나의 균주로 이루어지는 것인 미백 및 주름개선용 화장료 조성물.
A cosmetic composition for whitening and wrinkle improvement containing a fermented extract of sprouted oats ( Avena sativa ),
A cosmetic composition for whitening and wrinkle improvement, wherein the fermentation is performed using any one strain selected from the group consisting of Lactobacillus plantarum , Lactobacillus rhamnosus, Lactobacillus casei, and Lactobacillus gasseri.
상기 새싹귀리 추출물은 물, 탄소수 1 내지 4의 알코올 및 이들의 혼합물로 이루어진 군에서 선택되는 용매로 추출되는 것인 미백 및 주름개선용 화장료 조성물.
In the first paragraph,
A cosmetic composition for whitening and wrinkle improvement, wherein the sprouted oat extract is extracted with a solvent selected from the group consisting of water, alcohols having 1 to 4 carbon atoms, and mixtures thereof.
상기 새싹귀리 추출물의 발효물은 35 내지 40℃에서 40 내지 80시간 동안 배양된 것인 미백 및 주름개선용 화장료 조성물.
In the first paragraph,
A cosmetic composition for whitening and wrinkle improvement, wherein the fermented product of the above sprout extract is cultured at 35 to 40°C for 40 to 80 hours.
상기 새싹귀리 추출물의 발효물은 화장료 조성물 100 중량부에 대하여 0.01 내지 30.0 중량부로 포함되는 것인 미백 및 주름개선용 화장료 조성물.
In the first paragraph,
A cosmetic composition for whitening and wrinkle improvement, wherein the fermented product of the above sprout extract is contained in an amount of 0.01 to 30.0 parts by weight per 100 parts by weight of the cosmetic composition.
상기 미백 및 주름개선용 화장료 조성물은 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이로 이루어진 군에서 선택되는 어느 하나의 제형인 것인 미백 및 주름개선용 화장료 조성물.
In the first paragraph,
The above whitening and wrinkle-improving cosmetic composition is a whitening and wrinkle-improving cosmetic composition in any one formulation selected from the group consisting of a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, a surfactant-containing cleanser, an oil, a powder foundation, an emulsion foundation, a wax foundation, and a spray.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220024866A KR102699167B1 (en) | 2022-02-25 | 2022-02-25 | Oat sprout postbiotic composition having skin whitening and wrinkle improvement activity and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220024866A KR102699167B1 (en) | 2022-02-25 | 2022-02-25 | Oat sprout postbiotic composition having skin whitening and wrinkle improvement activity and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20230127504A KR20230127504A (en) | 2023-09-01 |
KR102699167B1 true KR102699167B1 (en) | 2024-08-23 |
Family
ID=87975253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220024866A KR102699167B1 (en) | 2022-02-25 | 2022-02-25 | Oat sprout postbiotic composition having skin whitening and wrinkle improvement activity and use thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102699167B1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102016027B1 (en) | 2018-06-04 | 2019-08-29 | 주식회사 익스플즌 | Cosmetics composition improving skin wrinkle and skin elasticity and cosmetics including the same |
KR20210137739A (en) * | 2020-05-11 | 2021-11-18 | 주식회사 위드바이오코스팜 | Manufacturing Method of Postbiotics Fermentation Product and Postbiotics Fermentation Product Made by the Same |
KR20220006892A (en) * | 2020-07-09 | 2022-01-18 | 주식회사 유렌코리아 | Manufacturing method of cosmetic composition for moisturizing and wrinkle improvement |
-
2022
- 2022-02-25 KR KR1020220024866A patent/KR102699167B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20230127504A (en) | 2023-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101685581B1 (en) | Compositions for improving skin wrinkle or moisture comprising Orostachys japonicus and composition prepared therefrom | |
KR20180038639A (en) | Cosmetic Composition with Fermentative Extract of Osmanthus fragrans | |
KR20130107386A (en) | Fermented snail extract and its cosmetic usage | |
KR101040508B1 (en) | Cosmetic Composition for Anti-aging and moisturizing of the Skin Comprising Phaseolus radiatus seed extracts by fermentation and enzyme treatment | |
KR101814498B1 (en) | Cosmetic Composition Containing the Mixed Extract of Eucalyptus Globulus Leaf and Trifolium Pratense Leaf | |
KR102076656B1 (en) | A cosmetic composition for improving skin aging comprising an extract of femented barley using lactobacillus sp. complex strain as an active ingredient | |
KR20210155987A (en) | Composition Comprising Complex Extract of seaweeds Fermented by Lactobacillus Brevis with Anti-Wrinkling and Elasticity, Antioxidant, and Skin Hydration Property as Active Ingredient | |
KR101855206B1 (en) | Cosmetic Composition Comprising the Fermented Extract of Panax ginseng | |
KR102010235B1 (en) | Cosmetic composition having skin whitening effect | |
KR20210060801A (en) | Cosmetic Compositions for Anti-aging Comprising Complex Fermented Product of Plants | |
KR102699167B1 (en) | Oat sprout postbiotic composition having skin whitening and wrinkle improvement activity and use thereof | |
KR20120092229A (en) | Cosmetic composition comprising the fermented extracts of tissue cultures of brassica napus l, punica granatum and panax ginseng) | |
KR20160045289A (en) | Cosmetic Composition for Whitening of the Skin Comprising the Extract of Fermented Zea Mays Silk | |
KR101843976B1 (en) | Cosmetic composition comprising extract of geminated phaseolus radiatus fermented by aureobasidium pullulans | |
KR20180041351A (en) | Cosmetic Composition for Whitening of the Skin Comprising the Extract of Fermented Tillandsia usneoides | |
KR20190030395A (en) | Cosmetic Composition Containing Extracts of Blackberry and Cranberry | |
KR102098695B1 (en) | Cosmetic Composition Containing Extracts of Morus Alba Root and Paeonia Suffruticosa Root | |
KR20110105243A (en) | Cosmetic composition for the skin whitening comprising phaseolus radiatus seed extracts by fermentation and enzyme treatment | |
KR20110122448A (en) | Cosmetic composition comprising the extract of filipendula formosa as active ingredient | |
KR101167606B1 (en) | Cosmetic Composition for the Skin Whitening Comprising the Fermented Extract of Mallotus japonicus | |
KR20160087507A (en) | cosmetic composition containing Phaseolus Radiatus Seed, Phaseolus Vulgaris (Kidney Bean) Seed and Black Soybean extracts by fermentation and enzyme treatment | |
KR102298453B1 (en) | Cosmetic Composition for Whitening Skin Comprising Extract of Fermented Philodendron bipinnatifidum | |
KR20090068397A (en) | Cosmetic composition with the effect of calming skins | |
KR20210025757A (en) | Cosmetic Composition Containing Mixture Extracts of Phaseolus Radiatus Seed, Betula Alba Juice and Rumex Crispus Root | |
KR102688754B1 (en) | Preparation method of mandarin blossom ferment extract and Cosmetic composition for improving skin inflammation and reducing skin irritation containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |